Piper Sandler lowered the firm’s price target on Omnicell (OMCL) to $55 from $57 and keeps an Overweight rating on the shares. The firm notes the company raised 2025 guidance on Q2 strength across both segments and a dynamic China tariff situation. Piper updates its product gross margin forecast for the second half of 2025 and 2026 to reflect management’s latest commentary and the expectation that mitigation efforts eliminate effectively all China tariff impact by Q4 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL: